Stockscreener 앱 받기
0.00
100.00%
-1.35
전일 마감가:
$1.35
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$8.52M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$3.80
Chromocell Therapeutics Corp Stock (CHRO) Company Profile
명칭
Chromocell Therapeutics Corp
전화
(917) 644-6313
주소
685 US HIGHWAY ONE, NORTH BRUNSWICK
CHRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CHRO
Chromocell Therapeutics Corp
|
0.00 | 8.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Chromocell Therapeutics Corp 주식(CHRO)의 최신 뉴스
Pelthos Therapeutics target adjusted at Alliance after merger, reverse split - TipRanks
Pelthos Therapeutics shares rise 6.99% after-hours following CEO changes announcement. - AInvest
Pelthos Therapeutics Inc. announced that it has received $50 million in funding from Murchinson Ltd. and other investors - MarketScreener
Ligand Unit Completes Merger With Channel Subsidiary to Form Pelthos Therapeutics - MarketScreener
Channel Therapeutics Announces Reverse Common Stock Split - GlobeNewswire
Channel Therapeutics Faces Financial Uncertainty as Auditors Issue Going Concern Warning - Stock Titan
Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics - marketscreener.com
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings - Benzinga
Ligand subsidiaries, Chromocell Therapeutics to merge - TipRanks
Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics - marketscreener.com
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewswire Inc.
Channel Therapeutics Corporation announced that it has received $0.25 million in funding -February 24, 2025 - Marketscreener.com
Channel Therapeutics secures $325,000 promissory note By Investing.com - Investing.com Australia
Channel Therapeutics secures $325,000 promissory note - Investing.com India
New Biotech Stocks at Investorideas.com - Investorideas.com newswire
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld MedTech
Channel Therapeutics Advances Novel Pain Treatment Strategy with NaV1.7 Inhibitor Pipeline - Stock Titan
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - Yahoo Finance
Channel Therapeutics finalizes corporate restructuring - Investing.com
Chromocell Announces Amendment to Stock Repurchase Plan - The Manila Times
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - GlobeNewswire
Chromocell to Participate in Life Sciences Investor Forum September 19th - Yahoo Finance
CDMO Benuvia Appoints Terry Novak As New CEO - Pharmaceutical Online
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld MedTech
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn't fully recovered just yet - CNBC
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session - TradingView
Chutes & Ladders—Bayer undergoes leadership shake-up - Fierce Biotech
Are there bright times for biotech IPOs ahead? - European Biotechnology Magazine
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 - MarketScreener
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million - Yahoo Finance
CHRO Stock Price and Chart — AMEX:CHRO - TradingView
Pelthos Therapeutics Inc Stock Price Today | NYSE: PTHS Live - Investing.com
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering - Yahoo Finance
CHRO IPO NewsPain relief biotech Chromocell Therapeutics sets terms for $9 million IPO - renaissancecapital.com
Biotech Venture in the UAE Validated by IPO in the U.S. - PR Newswire
Tina Garyantes – Feliciano Center For Entrepreneurship And Innovation - Montclair State University
Nestlé and Chromocell Extend Collaboration to Find Alternatives to Salt - Food Manufacturing
Improving the Reliability and Utility of Streptozotocin‐Induced Rat Diabetic Model - Wiley Online Library
Chromocell Announces Initiation of Multiple Ascending Doses Portion of Phase 1 Clinical Trial - PR Newswire
Chromocell and Astellas Announce FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN - PR Newswire
News from Central Jersey's pharma, biotech industries - Central New Jersey News
Astellas, Chromocell Launch Up-to-$515M+ Pain Drugs Collaboration - Genetic Engineering and Biotechnology News
Chromocell Therapeutics Corp (CHRO) 재무 분석
Chromocell Therapeutics Corp (CHRO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.96%
1.09%
자본화:
|
볼륨(24시간):